Simnotrelvir/ritonavir (trade name Xiannuoxin) is a pharmaceutical drug used for the treatment of COVID-19.

It was developed by Simcere Pharmaceutical and conditionally approved in China by the National Medical Products Administration (NMPA) in January 2023.

[4] Results for the phase Ib trial are available.

[5] In a phase II/III trial, it reduced the duration of symptoms by a median of 36 hours compared to placebo.

[6] This antiinfective drug article is a stub.